Uterine fibroids and endometriosis are the most common benign gynecological diseases; however, their diagnostic and therapeutic protocols are still widely debated. Patients with uterine fibroids present with a wide range of symptoms depending on the size and location of the lesions; therefore, ultrasound and MRI play a major role in the diagnostic strategy. Abnormal uterine bleeding is the most frequent symptom that prompts patients to seek medical attention and requires treatment.

Surgery has long been considered the primary therapeutic option, but it is associated with multiple complications and a significant risk of recurrence. Consequently, new medical treatments, such as oral GnRH antagonists including linzagolix, are now available. These therapies are proposed not only to control symptoms but also to reduce fibroid volume, either in the context of fertility preservation or as a bridge to menopause.

Endometriosis is a highly painful condition characterized by dysmenorrhea, chronic pelvic pain, and often infertility. Diagnosis is challenging because ectopic endometrial lesions are frequently too small to be clearly identified by ultrasound or MRI, although advances in imaging technologies are improving detection. These diagnostic limitations also contribute to the high rate of surgical failure reported in endometriosis.

The use of linzagolix offers the possibility of suppressing ovarian hormone secretion and reducing pain, even over long periods when combined with appropriate add-back therapy.